ZD1839

ZD1839 (also known as Gefitinib) is a drug used in the treatment of certain types of cancer. It is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase and is marketed by AstraZeneca under the trade name Iressa.

Mechanism of Action

ZD1839 works by blocking the action of a protein called epidermal growth factor receptor (EGFR). This protein is often overactive in cancer cells, causing them to grow and divide more rapidly than normal cells. By blocking the action of EGFR, ZD1839 can slow the growth of cancer cells.

Uses

ZD1839 is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is used when other treatments have not worked or are not suitable. It is also being studied in the treatment of other types of cancer.

Side Effects

Common side effects of ZD1839 include skin rash, diarrhea, and feeling sick (nausea). Less common side effects include loss of appetite, vomiting, and weakness. In rare cases, ZD1839 can cause serious lung problems.

History

ZD1839 was approved by the Food and Drug Administration (FDA) in 2003 for the treatment of non-small cell lung cancer. It was the first drug of its kind to be approved for this use.

See Also

• Epidermal growth factor receptor
• Non-small cell lung carcinoma
• AstraZeneca

ZD1839 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia